TABLE 2.
The cumulative adverse cardiovascular and cerebral event incidence rates per the annual height decrease rate.
| All | Male | Female | |||||||
|
|
|||||||||
| Annual rate of height decrease†† | Annual rate of height decrease†† | Annual rate of height decrease†† | |||||||
|
|
|||||||||
| Group 1 | Group 2 | Group 3 | Group 1 | Group 2 | Group 3 | Group 1 | Group 2 | Group 3 | |
|
|
|
|
|||||||
| (N = 102,554) | (N = 17,324) | (N = 7,695) | (N = 48,053) | (N = 6,780) | (N = 2,790) | (N = 54,501) | (N = 10,544) | (N = 4,905) | |
|
|
|
|
|||||||
| Cumulative incidence rate† | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| MACCE | |||||||||
| 1st year | 892 (0.9) | 205 (1.2) | 95 (1.2) | 501 (1.0) | 97 (1.4) | 42 (1.5) | 391 (0.7) | 108 (1.0) | 53 (1.1) |
| 2nd year | 1,817 (1.8) | 391 (2.3) | 183 (2.4) | 1,006 (2.1) | 176 (2.6) | 78 (2.8) | 811 (1.5) | 215 (2.0) | 105 (2.1) |
| 3rd year | 2,696 (2.6) | 580 (3.4) | 295 (3.8) | 1,473 (3.1) | 255 (3.8) | 124 (4.4) | 1,223 (2.2) | 325 (3.1) | 171 (3.5) |
| 4th year | 3,687 (3.6) | 785 (4.5) | 401 (5.2) | 2,042 (4.3) | 338 (5.0) | 169 (6.1) | 1,645 (3.0) | 447 (4.2) | 232 (4.7) |
| All | 9,092 (8.9) | 1,961 (11.3) | 974 (12.7) | 5,022 (10.5) | 866 (12.8) | 413 (14.8) | 4,070 (7.5) | 1,095 (10.4) | 561 (11.4) |
| Cardiac death | |||||||||
| 1st year | 24 (0.0) | 5 (0.0) | 6 (0.1) | 18 (0.0) | 3 (0.0) | 3 (0.1) | 6 (0.0) | 2 (0.0) | 3 (0.1) |
| 2nd year | 85 (0.1) | 12 (0.1) | 9 (0.1) | 58 (0.1) | 7 (0.1) | 6 (0.2) | 27 (0.1) | 5 (0.1) | 3 (0.1) |
| 3rd year | 149 (0.2) | 29 (0.2) | 23 (0.3) | 94 (0.2) | 16 (0.2) | 11 (0.4) | 55 (0.1) | 13 (0.1) | 12 (0.2) |
| 4th year | 245 (0.2) | 50 (0.3) | 42 (0.6) | 155 (0.3) | 27 (0.4) | 19 (0.7) | 90 (0.2) | 23 (0.2) | 23 (0.5) |
| All | 503 (0.5) | 96 (0.6) | 80 (1.1) | 325 (0.7) | 53 (0.8) | 39 (1.4) | 178 (0.3) | 43 (0.4) | 41 (0.8) |
| Non-fatal MI | |||||||||
| 1st year | 114 (0.1) | 31 (0.2) | 10 (0.1) | 84 (0.2) | 20 (0.3) | 6 (0.2) | 30 (0.1) | 11 (0.1) | 4 (0.1) |
| 2nd year | 232 (0.2) | 52 (0.3) | 21 (0.3) | 159 (0.3) | 30 (0.4) | 12 (0.4) | 73 (0.1) | 22 (0.2) | 9 (0.2) |
| 3rd year | 365 (0.4) | 75 (0.4) | 36 (0.5) | 252 (0.5) | 44 (0.7) | 22 (0.8) | 113 (0.2) | 31 (0.3) | 14 (0.3) |
| 4th year | 504 (0.5) | 100 (0.6) | 51 (0.7) | 351 (0.7) | 55 (0.8) | 31 (1.1) | 153 (0.3) | 45 (0.4) | 20 (0.4) |
| All | 1,215 (1.2) | 258 (1.5) | 118 (1.5) | 846 (1.8) | 149 (2.2) | 71 (2.6) | 369 (0.7) | 109 (1.0) | 47 (1.0) |
| Stroke | |||||||||
| 1st year | 737 (0.7) | 171 (1.0) | 72 (0.9) | 394 (0.8) | 79 (1.2) | 30 (1.1) | 343 (0.6) | 92 (0.9) | 42 (0.9) |
| 2nd year | 1,472 (1.4) | 323 (1.9) | 149 (1.9) | 781 (1.6) | 140 (2.1) | 60 (2.2) | 691 (1.3) | 183 (1.7) | 89 (1.8) |
| 3rd year | 2,154 (2.1) | 464 (2.7) | 227 (3.0) | 1,122 (2.3) | 193 (2.9) | 89 (3.2) | 1,032 (1.9) | 271 (2.6) | 138 (2.8) |
| 4th year | 2,876 (2.8) | 620 (3.6) | 296 (3.9) | 1,520 (3.2) | 255 (3.8) | 116 (4.2) | 1,356 (2.5) | 365 (3.5) | 180 (3.7) |
| All | 7,239 (7.1) | 1,578 (9.1) | 744 (9.7) | 3,817 (7.9) | 667 (9.8) | 295 (10.6) | 3,422 (6.3) | 911 (8.6) | 449 (9.2) |
| Hospitalization for HF | |||||||||
| 1st year | 56 (0.1) | 11 (0.1) | 8 (0.1) | 35 (0.1) | 6 (0.1) | 3 (0.1) | 21 (0.0) | 5 (0.1) | 5 (0.1) |
| 2nd year | 116 (0.1) | 27 (0.2) | 14 (0.2) | 69 (0.1) | 17 (0.3) | 6 (0.2) | 47 (0.1) | 10 (0.1) | 8 (0.2) |
| 3rd year | 177 (0.2) | 47 (0.3) | 29 (0.4) | 103 (0.2) | 24 (0.4) | 11 (0.4) | 74 (0.1) | 23 (0.2) | 18 (0.4) |
| 4th year | 270 (0.3) | 65 (0.4) | 42 (0.6) | 152 (0.3) | 28 (0.4) | 17 (0.6) | 118 (0.2) | 37 (0.4) | 25 (0.5) |
| All | 619 (0.6) | 150 (0.9) | 93 (1.2) | 359 (0.7) | 75 (1.1) | 37 (1.3) | 260 (0.5) | 75 (0.7) | 56 (1.1) |
MACCE, major adverse cardiovascular and cerebral events; MI, myocardial infarction; HF, heart failure.
†After observing the degrees of height reduction for 10 years from 2002, we calculated the cumulative incidence rate of MACCE from January 2012 annually.
††Annual rate of height decrease: Group 1 (<0.3 cm), Group 2 (0.3 to <0.6 cm), and Group 3 (≥0.6 cm).